Logo

GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma

Share this

GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma

Shots:

  • The P-III CAPTAIN study involves assessing of Trelegy Ellipta (FF/UMEC/VI) (100/31.25/25- 100/62.5/25- 200/31.25/25 and 200/62.5/25 mcg) vs Relvar/Breo Ellipta (FF/VI) (100/25 and 200/25 mcg) in 2-436 patients with uncontrolled asthma prior treated with ICS/LABA across 15 countries
  • The P-III CAPTAIN study results: met its 1EPs; @24wks. 100/62.5/25mcg vs 200/62.5/25mcg- improvement in lung function & trough FEV1 (110ml &r 92ml); 100/62.5/25 and 200/62.5/25 vs 100/25 and 200/25- 13% reduction in exacerbations
  • Trelegy Ellipta (qd) is an inhaler triple therapy of fluticasone furoate/umeclidinium/vilanterol indicated for the maintenance treatment of airflow obstruction in COPD. In 2017- Trelegy Ellipta (100/62.5/25 mcg) has received FDA’s approval for COPD

Ref: GSK | Image: GSK

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions